Mining and analysis of adverse drug reaction signals of melphalan based on FAERS
- VernacularTitle:基于FAERS的美法仑不良反应信号挖掘与分析
- Author:
Panpan DI
1
;
Hai LIANG
2
;
Jie WANG
3
;
Yunfei HU
4
;
Shuyun JIA
1
Author Information
1. Pharmacy Intravenous Admixture Services，the Affiliated Bozhou Hospital of Anhui Medical University，Anhui Bozhou 236800，China
2. Dept. of Pharmacy，the Affiliated Bozhou Hospital of Anhui Medical University，Anhui Bozhou 236800，China
3. School of Public Basic Medicine，Bengbu Medical College，Anhui Bengbu 233030，China
4. College of Traditional Chinese Medicine，Bozhou University，Anhui Bozhou 236800，China
- Publication Type:Journal Article
- Keywords:
melphalan;
FAERS database;
adverse drug reactions;
data mining;
disproportional method
- From:
China Pharmacy
2023;34(12):1493-1497
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To mine the adverse drug reaction （ADR） signals of melphalan， so as to provide reference for clinically safe drug use. METHODS Using OpenVigil 2.1 data platform， relative ADR reports of melphalan from the first quarter of 2004 to the second quarter of 2022 in FAERS database were collected； data mining was conducted using the reported odds ratio （ROR） method and Medicines and Healthcare Products Regulatory Agency （MHRA） method of disproportional method. ADR reports were described and classified according to the system organ class （SOC） and preferred term （PT） in Medical Dictionary for Regulatory Activities （24.0 edition）. RESULTS A total of 17 046 ADR reports related to the target drug melphalan were retrieved， and the number of ADR reports showed a fluctuating upward trend； the majority of patients were male （43.28%）， and were concentrated between the ages of 50-＜75 （35.09%）， with the main reporting country being the United States （23.97%）； ADR report involved a total of 22 842 severe outcomes， mainly including hospitalization or extended hospitalization （24.45%）. Totally 403 ADR signals were detected， involving 23 SOC， mainly including blood and lymphatic system diseases （801 cases， 13.77%）， followed by eye organ diseases （755 cases， 12.97%） and infectious and invasive diseases （716 cases， 12.30%）. The ADR signals ranked high in the number of reported cases included febrile neutropenia， diarrhea， fever and mucositis and other PT； PT such as pneumonia， sepsis， vitreous hemorrhage， chorioretinal atrophy， myelodysplastic syndrome were not recorded in drug instructions. The ADR signals with high signal strength ranking included choroidal dystrophy， chorioretinal atrophy， eyeball atrophy and other PT， and above three types of PT were not included in the drug instructions. CONCLUSIONS ADRs caused by melphalan mainly include blood and lymphatic system diseases， eye organ diseases， and infectious and invasive diseases； before using melphalan， it is necessary to evaluate the drug use of patients， and pay close attention to the patient’s blood indicators and eye toxicity reaction， so as to guarantee the safety of treatment.
